WO2000017358A3 - Human chaperone proteins - Google Patents

Human chaperone proteins Download PDF

Info

Publication number
WO2000017358A3
WO2000017358A3 PCT/US1999/022027 US9922027W WO0017358A3 WO 2000017358 A3 WO2000017358 A3 WO 2000017358A3 US 9922027 W US9922027 W US 9922027W WO 0017358 A3 WO0017358 A3 WO 0017358A3
Authority
WO
WIPO (PCT)
Prior art keywords
chaperone proteins
hchp
human chaperone
provides
expression
Prior art date
Application number
PCT/US1999/022027
Other languages
French (fr)
Other versions
WO2000017358A2 (en
Inventor
Y Tom Tang
Jennifer L Hillman
Henry Yue
Chandra Patterson
Mariah R Baughn
Sajeev Batra
Original Assignee
Incyte Genomics Inc
Y Tom Tang
Jennifer L Hillman
Henry Yue
Chandra Patterson
Mariah R Baughn
Sajeev Batra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Y Tom Tang, Jennifer L Hillman, Henry Yue, Chandra Patterson, Mariah R Baughn, Sajeev Batra filed Critical Incyte Genomics Inc
Priority to CA002343718A priority Critical patent/CA2343718A1/en
Priority to EP99969442A priority patent/EP1115864A2/en
Priority to AU60582/99A priority patent/AU6058299A/en
Priority to JP2000574257A priority patent/JP2004504002A/en
Publication of WO2000017358A2 publication Critical patent/WO2000017358A2/en
Publication of WO2000017358A3 publication Critical patent/WO2000017358A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

The invention provides human chaperone proteins (HCHP) and polynucleotides which identify and encode HCHP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HCHP.
PCT/US1999/022027 1998-09-22 1999-09-22 Human chaperone proteins WO2000017358A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002343718A CA2343718A1 (en) 1998-09-22 1999-09-22 Human chaperone proteins
EP99969442A EP1115864A2 (en) 1998-09-22 1999-09-22 Human chaperone proteins
AU60582/99A AU6058299A (en) 1998-09-22 1999-09-22 Human chaperone proteins
JP2000574257A JP2004504002A (en) 1999-01-19 1999-09-22 Human chaperone protein

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US60/172.221 1998-09-22
US17221699A 1999-01-19 1999-01-19
US23329199A 1999-01-19 1999-01-19
US09/233,291 1999-01-19
US17223299P 1999-04-19 1999-04-19
US60/172,232 1999-04-19

Publications (2)

Publication Number Publication Date
WO2000017358A2 WO2000017358A2 (en) 2000-03-30
WO2000017358A3 true WO2000017358A3 (en) 2000-07-20

Family

ID=27390095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022027 WO2000017358A2 (en) 1998-09-22 1999-09-22 Human chaperone proteins

Country Status (4)

Country Link
EP (1) EP1115864A2 (en)
JP (1) JP2004504002A (en)
AU (1) AU6058299A (en)
WO (1) WO2000017358A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114175B2 (en) 2005-08-12 2015-08-25 Amgen Inc. Modified Fc molecules

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646249A (en) * 1994-02-28 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Isolation and characterization of a novel chaperone protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646249A (en) * 1994-02-28 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Isolation and characterization of a novel chaperone protein

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BAUER M. ET AL.: "Genetic and functional characterization of the human mitochondrial inner membrane translocase", JOURNAL OF MOLECULAR BIOLOGY, vol. 289, no. 1, May 1999 (1999-05-01), pages 69 - 82, XP000874019 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002128905, Database accession no. AI798647 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002128913, Database accession no. U69898 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002128914, Database accession no. AB006452 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002128915, Database accession no. AF041254 *
DATABASE SWISSPROT 1 January 1900 (1900-01-01), XP002128904, Database accession no. O43615 *
JUN WADA ET AL.: "Characterization of mammalian translocase of inner mitochondrial membrane (Tim44) isolated from diabetic newborn mouse kidney", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 95, no. 1, 6 January 1998 (1998-01-06), WASHINGTON US, pages 144 - 149, XP002128903 *
NAOTADA ISHIHARA ET AL.: "Identification of the protein import components of the rat mitochondrial inner membrane rTIM17, rTIM23, and rTIM44", THE JOURNAL OF BIOCHEMISTRY, vol. 123, no. 4, April 1998 (1998-04-01), pages 722 - 732, XP002071314 *
SABINE HOFMANN ET AL.: "Identification and characterization of the human preprotein translocase of the mitochondrial inner membrane", MOLECULAR BIOLOGY OF THE CELL, vol. 9, November 1998 (1998-11-01), pages 79A, XP000870416 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114175B2 (en) 2005-08-12 2015-08-25 Amgen Inc. Modified Fc molecules

Also Published As

Publication number Publication date
WO2000017358A2 (en) 2000-03-30
AU6058299A (en) 2000-04-10
JP2004504002A (en) 2004-02-12
EP1115864A2 (en) 2001-07-18

Similar Documents

Publication Publication Date Title
WO2001012662A3 (en) Membrane associated proteins
WO1999061471A3 (en) Human transmembrane proteins
WO2000000610A3 (en) Human signal peptide-containing proteins
WO2000015793A3 (en) Human gpcr proteins
WO2000021988A3 (en) Human ankyrin family protein
WO2000018922A3 (en) Human carbohydrate-associated proteins
WO2000034477A3 (en) Neuron-associated proteins
WO1999058692A3 (en) Human apoptosis associated proteins
WO2000009709A3 (en) Proteases and associated proteins
WO2000026245A3 (en) Human membrane transport proteins
WO2000012703A3 (en) Protein transport-associated molecules
WO2000017355A3 (en) Human cytoskeleton associated proteins
WO2001007612A3 (en) Receptors and associated proteins
WO2001020004A3 (en) Protein phosphatase and kinase proteins
WO2000052151A3 (en) Human secretory proteins
WO2000078953A3 (en) Human transport proteins
WO2000014251A3 (en) Human transferase proteins
WO1999058558A3 (en) Cell signaling proteins
WO1999061614A3 (en) Human socs proteins
WO2001044448A3 (en) Human oxidoreductase proteins
WO2000031263A3 (en) Gtpase associated proteins
WO2000028045A3 (en) Human hydrolase proteins
WO2000042201A3 (en) Human peptidases
WO2000065054A3 (en) Human membrane-associated proteins
WO2000008155A3 (en) Human receptor-associated proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2343718

Country of ref document: CA

Ref country code: CA

Ref document number: 2343718

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 574257

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999969442

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999969442

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09787678

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999969442

Country of ref document: EP